Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022

Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022

Strasbourg, France, March 9, 2022, 8:00 am CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer will be presenting a poster with new and promising preliminary Phase I data on TG4050, its individualized neoantigen cancer vaccine, at the AACR (American Association for Cancer Research) Annual Meeting 2022. AACR will take place in New Orleans, Louisiana, USA, April 8 – 13.

The abstract has been accepted for a late-breaking session and will be made available on the AACR Online Itinerary Planner and Meeting App on April 8, 2022.

TG4050 is the first candidate based on Transgene’s myvac® platform. Powered by NEC’s cutting-edge AI capabilities, TG4050 is being evaluated in two ongoing multicenter Phase I trials in patients with ovarian cancer and head and neck cancer.

Poster title: Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients

• Session title: Phase I Clinical Trials 2
• Poster and abstract number: CT182
• Date, time, location: Tuesday Apr 12, 2022 9:00 AM - 12:30 PM CDT, Board 7, Section 33
• Authors: M. Block, JP Delord, C. Ottensmeier, C. Le Tourneau, A. Lalanne, O. Lantz, K. Knutson, G. Lacoste, A. Tavernaro, M. Brandely, N. Silvestre, B. Grellier, Y. Yamashita, O. Kousuke, N. Yamagata, E. Quemeneur, K. Bendjama